THDBH120 / Tonghua Dongbao, WuXi AppTec - LARVOL DELTA

A novel GIPR/GLP-1R dual agonist improves systemic metabolism through differentially regulating inflammation and lipid metabolism in obesity. (PubMed, J Adv Res) - "Both GLP-1R and GIPR are important in mediating the beneficial effects of dual receptors on systemic metabolism. THDBH120 is a novel long-acting dual GIPR/GLP-1R agonist that has potential clinical applications."

Journal • Diabetes • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Phase II Study of THDBH120 Injection in Overweight or Obese Subjects (clinicaltrials.gov) - P2 | N=276 | Recruiting | Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd

New P2 trial • Obesity

Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM (clinicaltrials.gov) - P1 | N=49 | Completed | Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With Obesity (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd

New P1 trial • Genetic Disorders • Obesity

A Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of THDBH120 Injection in Healthy Subjects (clinicaltrials.gov) - P1 | N=72 | Completed | Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd

New P1 trial